BR112012014471A2 - método para o tratamento de cicatrizes e de distúrbios mediados por beta-catenina usando compostos nefopam - Google Patents
método para o tratamento de cicatrizes e de distúrbios mediados por beta-catenina usando compostos nefopamInfo
- Publication number
- BR112012014471A2 BR112012014471A2 BR112012014471A BR112012014471A BR112012014471A2 BR 112012014471 A2 BR112012014471 A2 BR 112012014471A2 BR 112012014471 A BR112012014471 A BR 112012014471A BR 112012014471 A BR112012014471 A BR 112012014471A BR 112012014471 A2 BR112012014471 A2 BR 112012014471A2
- Authority
- BR
- Brazil
- Prior art keywords
- catenin
- nefopam
- disorders
- cancer
- compounds
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 6
- 208000035475 disorder Diseases 0.000 title abstract 6
- RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical class C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 title abstract 5
- 230000001404 mediated effect Effects 0.000 title abstract 3
- 102000015735 Beta-catenin Human genes 0.000 title abstract 2
- 108060000903 Beta-catenin Proteins 0.000 title abstract 2
- 208000032544 Cicatrix Diseases 0.000 title abstract 2
- 231100000241 scar Toxicity 0.000 title abstract 2
- 230000037387 scars Effects 0.000 title abstract 2
- 229960000751 nefopam Drugs 0.000 abstract 2
- 208000005748 Aggressive Fibromatosis Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010019043 Hair follicle tumour benign Diseases 0.000 abstract 1
- 208000000172 Medulloblastoma Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000006827 desmoid tumor Diseases 0.000 abstract 1
- 230000000893 fibroproliferative effect Effects 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 208000001095 pilomatrixoma Diseases 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000037390 scarring Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28663309P | 2009-12-15 | 2009-12-15 | |
| PCT/CA2010/002014 WO2011072394A1 (en) | 2009-12-15 | 2010-12-15 | METHOD OF TREATING SCARS AND ß-CATENIN-MEDIATED DISORDERS USING NEFOPAM COMPOUNDS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012014471A2 true BR112012014471A2 (pt) | 2017-06-06 |
Family
ID=44166687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012014471A BR112012014471A2 (pt) | 2009-12-15 | 2010-12-15 | método para o tratamento de cicatrizes e de distúrbios mediados por beta-catenina usando compostos nefopam |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US8957107B2 (enExample) |
| EP (1) | EP2512468B1 (enExample) |
| JP (1) | JP5792185B2 (enExample) |
| KR (1) | KR101753439B1 (enExample) |
| CN (2) | CN102781442B (enExample) |
| BR (1) | BR112012014471A2 (enExample) |
| CA (1) | CA2782472C (enExample) |
| DK (1) | DK2512468T3 (enExample) |
| ES (1) | ES2594900T3 (enExample) |
| WO (1) | WO2011072394A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102781442B (zh) * | 2009-12-15 | 2016-02-17 | 儿童医院 | 使用奈福泮化合物治疗瘢痕和β-联蛋白介导的疾病的方法 |
| US10736905B1 (en) | 2016-09-09 | 2020-08-11 | Shahin Fatholahi | Nefopam dosage forms and methods of treatment |
| EP4656191A1 (en) * | 2017-06-02 | 2025-12-03 | Iterion Therapeutics, Inc. | Methods for treatment of fibrotic diseases |
| US10736874B1 (en) | 2017-09-08 | 2020-08-11 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
| US11446311B2 (en) | 2017-09-08 | 2022-09-20 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
| US11266637B2 (en) * | 2018-06-01 | 2022-03-08 | Iterion Therapeutics, Inc. | Formulations of tegavivint and related compounds |
| CN110638780A (zh) * | 2019-09-11 | 2020-01-03 | 华益药业科技(安徽)有限公司 | 一种盐酸奈福泮片及其制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
| US6630142B2 (en) | 1999-05-03 | 2003-10-07 | Zymogenetics, Inc. | Method of treating fibroproliferative disorders |
| US6638981B2 (en) * | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
| US20030190308A1 (en) * | 2002-03-19 | 2003-10-09 | Braun Ralph P. | Adjuvant |
| GB0213869D0 (en) * | 2002-06-17 | 2002-07-31 | Arakis Ltd | The treatment of pain |
| PT1572672E (pt) | 2002-12-20 | 2008-10-02 | Sosei R & D Ltd | Benzoxazocinas e sua utilização como inibidores de reabsorção de monoamina |
| US20060019940A1 (en) | 2002-12-20 | 2006-01-26 | Baxter Andrew D | Novel benzoxazocines and their therapeutic use |
| GB0330049D0 (en) | 2003-12-24 | 2004-02-04 | Arakis Ltd | The treatment of neuropathic pain conditions |
| WO2005103019A1 (en) | 2004-04-21 | 2005-11-03 | Sosei R&D Ltd. | Benzoxazocines and their therapeutic use as monoamine reuptake inhibitors |
| GB2413322A (en) | 2004-04-21 | 2005-10-26 | Arakis Ltd | Nefopam analogues |
| CN1569004A (zh) * | 2004-05-13 | 2005-01-26 | 南昌弘益科技有限公司 | 盐酸奈福泮滴丸及其制备方法 |
| FR2880275B1 (fr) | 2005-01-06 | 2007-04-13 | Biocodex | Utilisation de composes pharmacologiques pour la prevention ou le traitement de la tolerance aigue aux morphiniques |
| GB0506835D0 (en) | 2005-04-04 | 2005-05-11 | Arakis Ltd | Therapeutic use of nefopam |
| GB0515703D0 (en) | 2005-07-29 | 2005-09-07 | Arakis Ltd | Therapeutic use of nefopam |
| CN101002756A (zh) | 2007-01-19 | 2007-07-25 | 陶燃 | 盐酸奈福泮的透皮贴片制剂 |
| GB0721013D0 (en) | 2007-10-25 | 2007-12-05 | Sosei R & D Ltd | New Salts |
| MX2010013931A (es) | 2008-06-16 | 2011-06-01 | Academia Sinica | Diagnosis de cancer basada en niveles de anticuerpos contra globo h y sus fragmentos. |
| GB2461874B (en) | 2008-07-14 | 2012-11-21 | Caltec Ltd | Separation system and method |
| FR2940911B1 (fr) * | 2009-01-13 | 2012-09-21 | Philippe Perovitch | Formulation pour l'administration par voie trans-muqueuse buccale de molecules antalgiques et/ou anti-spasmodiques |
| CN102781442B (zh) * | 2009-12-15 | 2016-02-17 | 儿童医院 | 使用奈福泮化合物治疗瘢痕和β-联蛋白介导的疾病的方法 |
-
2010
- 2010-12-15 CN CN201080057504.7A patent/CN102781442B/zh not_active Expired - Fee Related
- 2010-12-15 ES ES10836897.8T patent/ES2594900T3/es active Active
- 2010-12-15 KR KR1020127018272A patent/KR101753439B1/ko not_active Expired - Fee Related
- 2010-12-15 JP JP2012543426A patent/JP5792185B2/ja not_active Expired - Fee Related
- 2010-12-15 US US13/516,016 patent/US8957107B2/en active Active
- 2010-12-15 CN CN201610027616.7A patent/CN105687185B/zh not_active Expired - Fee Related
- 2010-12-15 WO PCT/CA2010/002014 patent/WO2011072394A1/en not_active Ceased
- 2010-12-15 EP EP10836897.8A patent/EP2512468B1/en not_active Not-in-force
- 2010-12-15 BR BR112012014471A patent/BR112012014471A2/pt not_active Application Discontinuation
- 2010-12-15 DK DK10836897.8T patent/DK2512468T3/en active
- 2010-12-15 CA CA2782472A patent/CA2782472C/en active Active
-
2014
- 2014-12-19 US US14/577,329 patent/US9566263B2/en active Active
-
2016
- 2016-12-24 US US15/390,468 patent/US20170172980A1/en not_active Abandoned
-
2017
- 2017-05-19 US US15/599,516 patent/US10722493B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011072394A1 (en) | 2011-06-23 |
| EP2512468B1 (en) | 2016-08-24 |
| US8957107B2 (en) | 2015-02-17 |
| HK1174565A1 (zh) | 2013-06-14 |
| CN105687185A (zh) | 2016-06-22 |
| US20150105363A1 (en) | 2015-04-16 |
| US9566263B2 (en) | 2017-02-14 |
| CN102781442A (zh) | 2012-11-14 |
| HK1224224A1 (zh) | 2017-08-18 |
| DK2512468T3 (en) | 2016-11-14 |
| CN105687185B (zh) | 2019-07-09 |
| CA2782472A1 (en) | 2011-06-23 |
| JP5792185B2 (ja) | 2015-10-07 |
| KR101753439B1 (ko) | 2017-07-19 |
| CA2782472C (en) | 2019-04-16 |
| US20170172980A1 (en) | 2017-06-22 |
| ES2594900T3 (es) | 2016-12-23 |
| US10722493B2 (en) | 2020-07-28 |
| KR20120110117A (ko) | 2012-10-09 |
| US20170281594A1 (en) | 2017-10-05 |
| EP2512468A4 (en) | 2013-08-07 |
| JP2013513625A (ja) | 2013-04-22 |
| CN102781442B (zh) | 2016-02-17 |
| EP2512468A1 (en) | 2012-10-24 |
| US20120294928A1 (en) | 2012-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121357T1 (el) | Νεος ανοσοτροποποιητης και αντιφλεγμονωδεις ενωσεις | |
| EA201591145A1 (ru) | Ингибиторы гистондеметилазы | |
| PH12017502141A1 (en) | Compounds and their methods of use | |
| MY171866A (en) | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | |
| BR112015023038A2 (pt) | composições para salto de exon para o tratamento da distrofia muscular | |
| BR112015023001A2 (pt) | composição de salto de exon para tratamento de distrofia muscular | |
| EA201100879A1 (ru) | Производные пиридопиримидина в качестве ингибиторов аутотаксина | |
| BR112012011195A2 (pt) | Oligonucleotídeo antissentido, composição e respectivo uso. | |
| MX352672B (es) | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. | |
| MX377405B (es) | Compuestos para el tratamiento de cáncer. | |
| UA107783C2 (en) | Isoindoline compounds for use in treating cancer | |
| CY1121037T1 (el) | Αντινοηματικα πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων | |
| CL2012001627A1 (es) | Compuestos derivados de 1,3-tiazol-fenilaminopirimidinas, inhibidores de syk; composición farmacéutica; y su uso para el tratamiento de la artritis reumatoide y cancer. | |
| MX2015015144A (es) | Potenciador de inhibidores del homologo de zeste. | |
| TN2012000559A1 (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer | |
| MX2019011424A (es) | Antagonistas de union al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cancer. | |
| MY165620A (en) | Cyclopropylamines as lsd1 inhibitors | |
| EA201391509A1 (ru) | Твердофазные формы кабазитаксела и способы их получения | |
| EA201390015A1 (ru) | Композиции и способы ингибирования пути jak | |
| GEP20156372B (en) | Pyridazinone compounds and their use as daao inhibitors | |
| IN2015DN00372A (enExample) | ||
| MX2011008885A (es) | Composiciones, sintesis y metodos para usar derivados de arilpiperazina. | |
| BR112012008546A2 (pt) | derivados de sulfóxido para o tratamento de tumor | |
| EP2337575A4 (en) | TREATMENT PROCEDURE WITH ORITAVANCIN SINGLE DOSES | |
| ATE542531T1 (de) | Nitrofuran-verbindungen zur behandlung von krebs und angiogenese |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
| B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
| B07E | Notice of approval relating to section 229 industrial property law |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |